Market Intelligence
Medical Devices Healthcare Thailand Exports Trade Development

Thailand Healthcare Non Communicable Diseases

Thailand’s Minister of Public Health has made reducing non-communicable diseases (NCDs) a top priority for 2025, as the diseases are costing the government upwards of $4.4 billion annually. This presents a significant opportunity for U.S. healthcare companies to expand their presence in a high-growth market while addressing a critical public health crisis.

In 2024, NCDs, including cancers, cardiovascular diseases, diabetes, and chronic obstructive pulmonary disease, were the leading cause of death in Thailand. NCDs killed nearly 400,000 people, accounting for 76 percent of all deaths.  75 percent of Thailand’s elderly population (7.4 million people) suffer from chronic NCDs. Nearly 25% of people aged 30-69 years old have NCDs.  

The overall prevalence of NCDs underscores the urgent need for better prevention, diagnosis, and treatment options. Approximately: 

  • 14 million Thais have high blood pressure.
  • 6.5 million have diabetes.
  • 1 million have kidney disease.
  • 140,000 have cancer.

Given Thailand’s health statistics above, high-potential business opportunities for U.S. healthcare companies include:

  • Pharmaceutical Products: innovative and cost-effective treatments for chronic conditions like diabetes, cardiovascular diseases, cancer, and chronic obstructive pulmonary disease, including branded and generic drugs.
  • Medical Devices and Diagnostics: advanced diagnostic tools and monitoring devices for early detection and effective management of NCDs, such as imaging systems, wearable health monitors, and remote patient monitoring devices.
  • Digital Health Solutions: telemedicine platforms, mobile health applications, and data analytics to enhance patient management, support remote care, and enable personalized treatment plans.
  • Healthcare Infrastructure and Training: collaborate with local stakeholders to improve healthcare facilities and provide training programs for medical professionals, ensuring the effective use of advanced technologies and treatment protocols.
  • Research and Development Partnerships: joint R&D initiatives to create therapies and technologies tailored to local health needs, including clinical trials and studies that address the unique aspects of NCDs in Thailand.

By targeting these areas, U.S. healthcare companies can play a vital role in reducing Thailand’s NCDs burden while also expanding their market presence and fostering sustainable growth in the region.  

For more information, Kornluck Tantisaeree, Commercial Specialist, CS Thailand, Email: Kornluck.tantisaeree@trade.gov